News

Two identical twins have the same disease-linked mutation in the complement factor B (CFB) gene, but only one developed atypical hemolytic uremic syndrome (aHUS), a recent study reports. Despite only one having aHUS, the identical, or monozygotic, twins had similar levels of complement system activity — a part of…

Soliris(eculizumab) was found to be effective in most patients with atypical hemolytic uremic syndrome (aHUS) when used as a rescue therapy for aHUS recurrence after a kidney transplant, according to a small study. However, many patients also showed persistent kidney failure at…

A substantial number of people with atypical hemolytic uremic syndrome (aHUS) carry rare structural variations in a part of the genome called the CFH-CFHR region and some variants are linked to certain disease manifestations, a recent study reports. “This work highlights the association between aHUS and genomic rearrangements in…

NovelMed has been cleared to begin patient testing of NM8074, an investigational antibody-based therapy for atypical hemolytic uremic syndrome (aHUS) that is not expected to carry a risk of treatment-related infections. The therapy candidate is designed to block the complement cascade — a part of the immune system…

A man with an HIV infection and secondary atypical hemolytic uremic syndrome (aHUS) was successfully treated with Soliris (eculizumab), a case study reported. “This case highlights the unusual presentation and [origin of aHUS], demonstrating the importance of recognizing therapeutic options in primary and secondary settings,” the researchers wrote…

Disease-causing variants in complement genes appear to be uncommon in children with atypical hemolytic uremic syndrome (aHUS) caused by autoantibodies against complement factor H (CFH), an Indian study found. The study, “Variants in complement genes are uncommon in patients with anti-factor H autoantibody-associated atypical hemolytic uremic syndrome,” was published…

Using Soliris (eculizumab) in combination with the blood cancer treatment obinutuzumab successfully prevented the recurrence of atypical hemolytic uremic syndrome (aHUS) after kidney transplant in a 45-year-old woman, a case study reported for the first time. The woman lost kidney function due to a rare occurrence of aHUS…

Vaccination against COVID-19 was linked to the onset or recurrence of atypical hemolytic uremic syndrome (aHUS) in three Dutch patients in a recent case report. Researchers didn’t find any additional cases wherein a vaccination could be tied to aHUS relapse in a retrospective analysis of 41 other aHUS patients…

Soliris (eculizumab) safely and effectively treated a 46-year-old man with atypical hemolytic uremic syndrome (aHUS) secondary to a scleroderma renal crisis — a life-threatening complication of an autoimmune disorder that can lead to kidney failure. His case was described in the study, “Atypical hemolytic-uremic syndrome due to a scleroderma renal crisis…

The demographics of people hospitalized for hemolytic uremic syndrome (HUS) in the U.S. have shifted over the last decade, with a lower proportion of young children and a higher number of Black patients, a new study reports. “Further surveillance is required to determine if these trends continue,” the researchers wrote.